Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues:
Total revenues	$ 22,823,000	$ 18,711,000	$ 68,266,000	$ 52,288,000
Cost of sales	(6,721,000)	(4,947,000)	(19,218,000)	(13,134,000)
Gross profit	16,102,000	13,764,000	49,048,000	39,154,000
Operating expenses:
Selling, general and administrative	15,421,000	11,356,000	43,004,000	28,643,000
Research and development	775,000	6,125,000	2,347,000	7,142,000
Total operating expenses	16,196,000	17,481,000	45,351,000	35,785,000
(Loss) income from operations	(94,000)	(3,717,000)	3,697,000	3,369,000
Other (expense) income:
Interest expense, net	(1,800,000)	(1,685,000)	(5,386,000)	(3,512,000)
Equity in losses of unconsolidated entities	(3,504,000)	(706,000)	(9,036,000)	(2,967,000)
Investment loss from Eton Pharmaceuticals	(1,031,000)	(2,220,000)	(4,341,000)	(8,639,000)
Loss on early extinguishment of debt				(756,000)
Gain on forgiveness of PPP loan				1,967,000
Other expense, net				(51,000)
Total other expense, net	(6,335,000)	(4,611,000)	(18,763,000)	(13,958,000)
Loss before income taxes	(6,429,000)	(8,328,000)	(15,066,000)	(10,589,000)
Income taxes	(35,000)		(75,000)
Net loss	(6,464,000)	(8,328,000)	(15,141,000)	(10,589,000)
Preferred dividends and accretion of preferred stock issuance costs				(472,000)
Net loss attributable to common stockholders	$ (6,464,000)	$ (8,328,000)	$ (15,141,000)	$ (11,061,000)
Basic and diluted net loss per share of common stock	$ (0.24)	$ (0.31)	$ (0.55)	$ (0.42)
Weighted average number of shares of common stock outstanding, basic and diluted	27,349,642	27,112,531	27,293,756	26,626,722
Product Sales, Net [Member]
Revenues:
Total revenues	$ 21,575,000	$ 17,811,000	$ 63,433,000	$ 50,056,000
Other Revenues [Member]
Revenues:
Total revenues	$ 1,248,000	$ 900,000	$ 4,833,000	$ 2,232,000